Amgen Posts 77% Response In Thyroid Eye Disease Study

Amgen Inc. (NASDAQ:AMGN) shares are down on Monday after the company announced topline results from a Phase 3 trial of TEPEZZA, which is administered via an on-body injector for patients with moderate-to-severe active Thyroid Eye Disease. Trial Meets Primary Endpoint...

CrowdStrike Unveils $500 Million Buyback Boost

CrowdStrike Holdings Inc. (NASDAQ:CRWD) said Monday its board has approved an additional $500 million for its share repurchase program, lifting the total authorization to $1.5 billion. Boosts Share Buyback The company has already repurchased 413,130 shares of its...